Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Glipizide/voglibose hypoglycemic oral preparation composition and preparation method thereof

A technology of voglibose and glipizide, applied in the pharmaceutical field, can solve problems such as poor insulin effect, weight loss, enhanced fat and protein decomposition, and achieve good patient compliance

Inactive Publication Date: 2016-06-22
HEILONGJIANG ZHICHENG MEDICAL TECH
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The ability to produce insulin in the body of patients with type 2 diabetes is not completely lost. Some patients even produce too much insulin in the body, but the effect of insulin is poor. Therefore, the insulin in the body of the patient is relatively deficient. insulin secretion
However, due to the absolute or relative lack of insulin or the insensitivity of tissues to insulin in diabetics, the ability of tissues to absorb and utilize glucose is reduced. ", thereby stimulating the feeding center, causing hunger and overeating; in addition, the body cannot make full use of glucose, and a large amount of glucose is excreted from the urine, so the body is actually in a semi-starved state, and the lack of energy also causes hyperphagia
[0010]4. Weight loss

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glipizide/voglibose hypoglycemic oral preparation composition and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Glipizide / voglibose hypoglycemic oral preparation, the main ingredient is composed of glipizide 2.5mg-5mg, voglibose 0.1mg-0.3mg, excipients include filler, disintegrant, adhesive Composed of additives and lubricants, the weight percentages of various raw materials are: main material 2-6%, filler 50-90%, disintegrant 5-15%, binder 0.1-30%, lubricant 0.01-5% %.

[0047] The filler is one or a mixture of microcrystalline cellulose, calcium sulfate, calcium phosphate and xylitol.

[0048] The disintegrating agent is one or more of low-substituted hydroxypropyl cellulose, sodium starch glycolate and croscarmellose sodium.

[0049] The binder is starch slurry or povidone k30 or hypromellose.

[0050] Described lubricant is the mixing of one or two in magnesium stearate, sodium lauryl sulfate.

Embodiment 2

[0052] Glipizide / voglibose hypoglycemic oral preparation and preparation method thereof, the specific steps of the preparation method are:

[0053] Step 1, select glipizide, voglibose, filler, disintegrant, binder, lubricant by weight percentage, pass through 80 mesh sieve respectively, set aside;

[0054] Step 2. Mix the sieved glipizide, voglibose, filler and disintegrant evenly, put the mixed raw and auxiliary materials into the wet granulator, and put the binder into the liquid supply tank In the middle, turn on the machine, adjust the parameters, and turn on the shear flying knife at the same time, 2-5 minutes, discharge, use the swing granulator, pass through the 14-18 mesh nylon screen to granulate;

[0055] Step 3. Put the wet granules in a fluidized bed coating machine, dry them at an air inlet temperature below 50°C, and keep the moisture below 4%;

[0056] Step 4, sizing the dry particles with a 16-20 mesh steel sieve;

[0057] Step 5, add lubricant, p...

Embodiment 3

[0060] Glipizide / voglibose hypoglycemic oral preparation and preparation method thereof, the formula determined by the following weight:

[0061] Glipizide 2.5mg-5mg

[0062] Voglibose 0.1mg-0.3mg

[0063] Filler 44.15mg-79.47mg

[0064] Disintegrant 4.415mg-13.245mg

[0065] Adhesive 0.0883mg-26.49mg

[0066] Lubricant 0.00883mg-4.415mg.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a glipizide / voglibose hypoglycemic oral preparation composition and a preparation method thereof, and the glipizide / voglibose hypoglycemic oral preparation composition comprises the following raw materials: 2-6% by weight of main components, 50-90% by weight of a filler, 5-15% by weight of a disintegrant, 0.1-3% by weight of a binder, 0.01-5% by weight of a lubricant. The main components comprise 2.5mg-5mg of glipizide and 0.1mg-0.3mg of voglibose, and auxiliary materials comprises the filler, the disintegrant, the binder and the lubricant. The glipizide / voglibose hypoglycemic oral preparation composition has the advantages of complementary main material action mechanism, multi targets, good patient compliance, and the like, and is more applicable to type 2 diabetes patients of which blood-glucose rises after meals and fasting blood-glucose rises insignificantly.

Description

technical field [0001] The invention belongs to the technical field of pharmacy, and in particular relates to a glipizide / voglibose hypoglycemic oral preparation and a preparation method thereof. Background technique [0002] Type 2 diabetes, formerly known as adult-onset diabetes, usually occurs after the age of 35 to 40, accounting for more than 90% of diabetic patients. The ability to produce insulin in the body of patients with type 2 diabetes is not completely lost, and some patients even produce too much insulin in the body, but the effect of insulin is poor, so the insulin in the body of the patient is relatively deficient, which can be stimulated by some oral drugs Insulin secretion. [0003] The symptoms of type II diabetes are related to metabolic disorders, especially "three excesses and one deficiency", which are often not very obvious or only partially manifested in type II diabetes; other manifestations are characterized by various acute and chronic complicati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/64A61K9/20A61P3/10A61K31/133
Inventor 张昕
Owner HEILONGJIANG ZHICHENG MEDICAL TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com